Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase 1/2a Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab

NCT03571568 is registered in ClinicalTrials.gov with BioInvent International AB as lead sponsor.

NCT NCT03571568
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03571568 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase 1/2a Trial of BI-1206, a Monoclonal Antibody to CD32b (FcyRIIB), in Combination With Rituximab With or Without Acalabrutinib in Subjects With Indolent B-Cell Non-Hodgkin Lymphoma That Has Relapsed or is Refractory to Rituximab
Lead sponsor
BioInvent International AB
Phase
Phase 1/2
Overall status
Recruiting
Start date
May 16, 2018
Completion date
September 30, 2027
Enrollment
140 (estimated)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

indolent b-cell non-hodgkin lymphoma